Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AMPE

AMPE - Ampio Pharmaceuticals Inc Stock Price, Fair Value and News

1.83USD-0.02 (-1.08%)Delayed as of 23 Feb 2024, 01:25 pm ET
Watchlist

Market Summary

USD1.83-0.02
Delayedas of 23 Feb 2024, 01:25 pm
-1.08%

AMPE Stock Price

View Fullscreen

AMPE RSI Chart

AMPE Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.17

Price/Sales (Trailing)

1.23

EV/EBITDA

0.16

Price/Free Cashflow

-0.15

AMPE Price/Sales (Trailing)

AMPE Profitability

EBT Margin

-2648.85%

Return on Equity

-163.68%

Return on Assets

-115.07%

Free Cashflow Yield

-685.34%

AMPE Fundamentals

AMPE Revenue

Revenue (TTM)

1.2M

AMPE Earnings

Earnings (TTM)

-8.8M

Earnings Growth (Yr)

80.83%

Earnings Growth (Qtr)

10.36%

Breaking Down AMPE Revenue

52 Week Range

1.88
(Low)(High)

Last 7 days

-3.9%

Last 30 days

-10.5%

Last 90 days

-34.2%

Trailing 12 Months

510.7%

How does AMPE drawdown profile look like?

AMPE Financial Health

Current Ratio

3.37

AMPE Investor Care

Shares Dilution (1Y)

10.31%

Diluted EPS (TTM)

-12.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20210000
20200000
20190000
20180000
20170000
20160000
201585.7K248.7K714.7K1.2M
201450.0K58.9K67.9K76.8K
201350.0K50.0K50.0K50.0K
201226.6K34.4K42.2K50.0K
201100018.8K

Tracking the Latest Insider Buys and Sells of Ampio Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 09, 2023
buchi j kevin
bought
6,284
0.2875
21,858
-
Jun 08, 2023
buchi j kevin
bought
7,400
0.296
25,000
-
May 24, 2023
martino michael a
bought
22,121
0.2877
76,890
ceo
May 16, 2023
buchi j kevin
bought
8,924
0.2743
32,534
-
May 15, 2023
buchi j kevin
bought
10,856
0.2466
44,026
-
May 12, 2023
buchi j kevin
bought
5,513
0.2352
23,440
-
May 12, 2023
stevens david r
bought
9,900
0.22
45,000
-
May 11, 2023
stevens david r
bought
10,875
0.2175
50,000
-
Jan 01, 2022
macaluso michael
sold (taxes)
-38,988
0.57
-68,400
-
Jan 01, 2022
cherevka holli
sold (taxes)
-26,904
0.57
-47,200
president and coo

1–10 of 47

Which funds bought or sold AMPE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Farther Finance Advisors, LLC
unchanged
-
-29.00
37.00
-%
Feb 15, 2024
Sunbelt Securities, Inc.
reduced
-4.63
-364
422
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
unchanged
-
-55.00
72.00
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
366
53.00
86.00
-%
Feb 14, 2024
Stonebridge Capital Advisors LLC
sold off
-100
-15.00
-
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
40,139
40,139
-%
Feb 14, 2024
Royal Bank of Canada
new
-
-
-
-%
Feb 13, 2024
FMR LLC
sold off
-100
-7.00
-
-%
Feb 13, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
-42.00
53.00
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
added
1,899
4,257
4,672
-%

1–10 of 42

Are Funds Buying or Selling AMPE?

Are funds buying AMPE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMPE
No. of Funds

Unveiling Ampio Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Dec 07, 2023
terker bruce e
0%
0
SC 13G/A
Feb 02, 2023
terker bruce e
6.36%
960,150
SC 13G/A
Jul 08, 2022
blackrock inc.
2.1%
4,699,064
SC 13G
Apr 29, 2022
terker bruce e
6.34%
14,402,231
SC 13G/A
Feb 04, 2022
blackrock inc.
6.2%
13,934,805
SC 13G
Jan 20, 2021
terker bruce e
5.96%
11,525,331
SC 13G/A
Jan 23, 2020
empery asset management, lp
1.15%
1,825,029
SC 13G/A
Jan 09, 2020
sabby management, llc
12.%
0
SC 13G/A
Jan 07, 2020
terker bruce e
7.26%
11,525,331
SC 13G/A

Recent SEC filings of Ampio Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 15, 2024
8-K
Current Report
Jan 25, 2024
8-K
Current Report
Jan 25, 2024
424B5
Prospectus Filed
Jan 24, 2024
424B5
Prospectus Filed
Jan 11, 2024
8-K
Current Report
Dec 21, 2023
S-1
Initial Public Offering
Dec 07, 2023
SC 13G/A
Major Ownership Report

Peers (Alternatives to Ampio Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Ampio Pharmaceuticals Inc News

Latest updates
InvestorsObserver09 Jan 202408:00 am

Ampio Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12023Q12022Q42022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-91,000-----------7,231,000682,000-------
Operating Expenses-64.5%1,560,0004,399,000--4,988,0006,970,0009,228,0003,851,0003,673,0003,819,0003,911,0003,302,0002,600,0006,021,000-------
  S&GA Expenses-68.2%1,216,0003,819,000--3,245,0003,283,0004,491,0001,257,0001,400,0001,523,0001,766,0001,647,0001,482,0001,767,000-------
  R&D Expenses-34.4%344,000524,000--1,743,0003,687,0004,737,0002,594,0002,273,0002,296,0002,145,0001,655,0001,118,0004,254,000-------
EBITDA Margin-0.8%-26.21-25.99-25.87-25.81-25.88-25.86-25.83-25.81-25.78-25.76-25.76----------
EBT Margin0%-26.49-26.49-26.49-26.49-26.49-26.49-26.49-26.49-26.49-26.49-26.49----------
Net Income65.5%-1,371,000-3,978,000---2,070,000-5,636,000-6,224,000-3,628,000-3,556,000-3,667,000-4,616,500-3,368,000-2,731,000-5,179,000-------
Net Income Margin4.8%-12.03-12.63-14.05-17.50-15.10-16.38-14.69-13.31-13.08-12.37-13.67----------
Free Cashflow-47.7%-3,399,000-2,301,000-4,294,000-5,943,000-5,947,000-4,944,000-3,704,000-3,926,000-2,328,000-4,228,000-2,895,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-16.4%8.009.0011.0014.0019.0027.0033.0039.0022.0027.0022.0023.0016.0012.009.0014.0016.0021.0013.0014.0016.00
  Current Assets-16.4%8.009.0011.0013.0018.0025.0030.0036.0019.0023.0018.0018.0011.007.003.008.0010.0014.006.008.009.00
    Cash Equivalents-8.0%6.007.0010.0013.0017.0023.0029.0034.0017.0021.0016.0017.009.005.002.007.008.0013.005.008.009.00
  Net PPE----0.000.002.002.003.003.003.003.004.004.004.004.005.005.005.006.006.006.00
Liabilities-12.3%2.003.003.002.005.007.0011.0012.005.006.005.005.005.006.007.008.0012.0010.0013.009.0013.00
  Current Liabilities-9.0%2.002.003.001.004.005.006.005.002.003.002.002.002.003.004.004.002.002.002.001.002.00
Shareholder's Equity-18.1%5.007.008.0012.0014.0020.0022.0027.0017.0020.0017.0018.0011.006.002.006.004.0011.001765.002.00
  Retained Earnings-0.5%-240-239-237-233-231-225-223-217-211-207-204-200-195-192-189-184-183-176-176-171-172
  Additional Paid-In Capital0.0%246246246246246245245245229228221218207199192191188187176176175
Shares Outstanding6.5%1.001.001.001.001.001.001.001.001.001.001.001.00---------
Float------37.00---330---106---54.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations83.7%-555-3,399-2,301-4,294-5,943-5,947-4,944-3,704-3,910-2,328-4,147-2,880-2,706-4,590-4,553-4,751-4,738-3,454-2,440-2,326-3,210
  Share Based Compensation-17.0%44.0053.0023.00669163-86.007162,44447.0067.0016652347764.0021358.0024673.0028.0015795.00
Cashflow From Investing----------16.00--81.00-15.00-48.00---8.00--9.00-5.00-78.25-43.62
Cashflow From Financing--------11120,4784957,0732,68610,8807,2737,0174363,247-11,08520.001,3187,265

AMPE Income Statement

2023-09-30
Condensed Statements of Operations - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 329,000$ 2,747,000$ 1,197,000$ 8,177,000
General and administrative1,071,0002,975,0006,106,0009,504,000
Long-lived assets impairment01,614,00001,614,000
Right of use asset impairment0322,0000322,000
Loss on sale of fixed assets0056,0000
Total operating expenses1,400,0007,658,0007,359,00019,617,000
Other income    
Interest income79,00080,000280,000116,000
Rental income92,0000213,0000
Gain from elimination of ARO obligation, net00288,0000
Derivative gain01,167,00005,384,000
Total other income171,0001,247,000781,0005,500,000
Net loss$ (1,229,000)$ (6,411,000)$ (6,578,000)$ (14,117,000)
Net loss per common share:    
Basic (in dollars per share)[1]$ (1.53)$ (8.51)$ (8.18)$ (18.73)
Diluted (in dollars per share)[1]$ (1.53)$ (10.06)$ (8.18)$ (25.88)
Weighted average number of common shares outstanding:    
Basic (in shares)[1]804,158753,620804,158753,616
Diluted (in shares)[1]804,158753,620804,158753,616
[1][1] Net loss per common share and weighted average number of common shares outstanding for the current period have been adjusted and the prior periods have been retroactively adjusted to reflect the 20-to-1 reverse stock split effected September 12, 2023.

AMPE Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 6,398,000$ 12,653,000
Insurance recovery receivable530,0000
Prepaid expenses and other718,000676,000
Total current assets7,646,00013,329,000
Fixed assets, net0184,000
Right-of-use asset, net075,000
Total assets7,646,00013,588,000
Current liabilities  
Accounts payable and accrued expenses1,909,000852,000
Lease liability-current portion362,000340,000
Total current liabilities2,271,0001,192,000
Lease liability-long-term0274,000
Warrant derivative liability044,000
Asset retirement obligation0289,000
Total liabilities2,271,0001,799,000
Commitments and contingencies (Note 5)
Stockholders' equity  
Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 804,604 as of September 30, 2023 and 804,674 as of December 31, 2022[1]
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; shares issued and outstanding - none as of September 30, 2023 and December 31, 2022
Additional paid-in capital245,848,000245,728,000[1]
Accumulated deficit(240,473,000)(233,939,000)
Total stockholders' equity5,375,00011,789,000
Total liabilities and stockholders' equity$ 7,646,000$ 13,588,000
[1]September 30, 2023 balances have been adjusted and December 31, 2022 balances have been retroactively adjusted to reflect the 20-to-1 reverse stock split effected September 12, 2023.
AMPE
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.
 CEO
 WEBSITEampiopharma.com
 EMPLOYEES8

Ampio Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Ampio Pharmaceuticals Inc? What does AMPE stand for in stocks?

AMPE is the stock ticker symbol of Ampio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ampio Pharmaceuticals Inc (AMPE)?

As of Thu Feb 22 2024, market cap of Ampio Pharmaceuticals Inc is 1.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPE stock?

You can check AMPE's fair value in chart for subscribers.

What is the fair value of AMPE stock?

You can check AMPE's fair value in chart for subscribers. The fair value of Ampio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ampio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMPE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ampio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPE is over valued or under valued. Whether Ampio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Ampio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPE.

What is Ampio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AMPE's PE ratio (Price to Earnings) is -0.17 and Price to Sales (PS) ratio is 1.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ampio Pharmaceuticals Inc's stock?

In the past 10 years, Ampio Pharmaceuticals Inc has provided -0.352 (multiply by 100 for percentage) rate of return.